Literature DB >> 30613980

Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status.

Robin Myte1, Björn Gylling2, Jenny Häggström3, Christel Häggström4,5, Carl Zingmark2, Anna Löfgren Burström2, Richard Palmqvist2, Bethany Van Guelpen1,6.   

Abstract

Factors related to energy metabolism and the metabolic syndrome, such as higher body mass index (BMI), blood glucose, or blood lipids, and blood pressure, are associated with an increased risk of colorectal cancer (CRC). However, CRC is a heterogeneous disease, developing through distinct pathways with differences in molecular characteristics and prognosis, and possibly also in risk factors. For subtypes defined by KRAS and BRAF mutation status, BMI is the only metabolic factor previously studied, with inconsistent findings. We investigated whether associations between BMI, blood glucose, blood lipids, and blood pressure and CRC risk differed by tumor KRAS and BRAF mutation status in 117,687 participants from two population-based cohorts within the Northern Sweden Health and Disease Study (NSHDS). Hazard ratios (HRs) for overall CRC and CRC subtypes by metabolic factors were estimated with Cox proportional hazards regression, using multiple imputation to handle missing exposure and tumor data. During a median follow-up of 15.6 years, we acquired 1,250 prospective CRC cases, of which 766 cases had complete baseline and molecular tumor data. Consistent with previous evidence, higher BMI, total cholesterol, triglyceride levels, and blood pressure were associated with an increased risk of overall CRC (HRs per 1 standard deviation increase: 1.07 to 1.12). These associations were similar regardless of CRC subtype by KRAS and BRAF mutation status (all pheterogeneity > 0.05). The same was true for subtypes based on microsatellite instability status. Poor metabolic health may therefore be a universal mechanism for colorectal cancer, acting across multiple developmental pathways.
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Entities:  

Keywords:  BRAF; KRAS; colorectal cancer; metabolic factors; microsatellite instability; risk factors

Mesh:

Substances:

Year:  2019        PMID: 30613980     DOI: 10.1002/ijc.32104

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases.

Authors:  Sophia Harlid; Bethany Van Guelpen; Conghui Qu; Björn Gylling; Elom K Aglago; Efrat L Amitay; Hermann Brenner; Daniel D Buchanan; Peter T Campbell; Yin Cao; Andrew T Chan; Jenny Chang-Claude; David A Drew; Jane C Figueiredo; Amy J French; Steven Gallinger; Marios Giannakis; Graham G Giles; Marc J Gunter; Michael Hoffmeister; Li Hsu; Mark A Jenkins; Yi Lin; Victor Moreno; Neil Murphy; Polly A Newcomb; Christina C Newton; Jonathan A Nowak; Mireia Obón-Santacana; Shuji Ogino; John D Potter; Mingyang Song; Robert S Steinfelder; Wei Sun; Stephen N Thibodeau; Amanda E Toland; Tomotaka Ugai; Caroline Y Um; Michael O Woods; Amanda I Phipps; Tabitha Harrison; Ulrike Peters
Journal:  Int J Cancer       Date:  2022-04-22       Impact factor: 7.316

2.  KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location.

Authors:  M Tabuso; M Christian; P K Kimani; K Gopalakrishnan; R P Arasaradnam
Journal:  Pathol Oncol Res       Date:  2020-06-27       Impact factor: 3.201

3.  Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases.

Authors:  Yaolin Song; Lili Wang; Wenwen Ran; Guangqi Li; Yujing Xiao; Xiaonan Wang; Li Zhang; Xiaoming Xing
Journal:  Front Genet       Date:  2020-02-25       Impact factor: 4.599

4.  Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer.

Authors:  Zhan Wang; Miao-Miao Wang; Yan Geng; Chen-Yang Ye; Yuan-Sheng Zang
Journal:  J Transl Med       Date:  2022-09-05       Impact factor: 8.440

5.  Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.

Authors:  Josien C A Jenniskens; Kelly Offermans; Colinda C J M Simons; Iryna Samarska; Gregorio E Fazzi; Jaleesa R M van der Meer; Kim M Smits; Leo J Schouten; Matty P Weijenberg; Heike I Grabsch; Piet A van den Brandt
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-11       Impact factor: 4.322

6.  Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis.

Authors:  Neil Murphy; Mingyang Song; Nikos Papadimitriou; Robert Carreras-Torres; Claudia Langenberg; Richard M Martin; Konstantinos K Tsilidis; Inês Barroso; Ji Chen; Timothy M Frayling; Caroline J Bull; Emma E Vincent; Michelle Cotterchio; Stephen B Gruber; Rish K Pai; Polly A Newcomb; Aurora Perez-Cornago; Franzel J B van Duijnhoven; Bethany Van Guelpen; Pavel Vodicka; Alicja Wolk; Anna H Wu; Ulrike Peters; Andrew T Chan; Marc J Gunter
Journal:  J Natl Cancer Inst       Date:  2022-05-09       Impact factor: 11.816

7.  Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction.

Authors:  Kenji Fujiyoshi; Yang Chen; Koichiro Haruki; Tomotaka Ugai; Junko Kishikawa; Tsuyoshi Hamada; Li Liu; Kota Arima; Jennifer Borowsky; Juha P Väyrynen; Melissa Zhao; Mai Chan Lau; Simeng Gu; Shanshan Shi; Naohiko Akimoto; Tyler S Twombly; David A Drew; Mingyang Song; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Reiko Nishihara; Jochen K Lennerz; Marios Giannakis; Jonathan A Nowak; Xuehong Zhang; Kana Wu; Shuji Ogino
Journal:  JNCI Cancer Spectr       Date:  2020-05-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.